Jubilant Generics will make the drug available to over 1,000 hospitals
providing Covid-19 treatment in India through its distribution
network, the company said in a release. Jubilant had entered into a
non-exclusive licensing agreement with US Gilead Sciences, Inc. In
May, which that granted it the right to register, manufacture and sell
Gilead's investigational drug Remdesivir in 127 countries including
India.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/jubilant-life-sciences-arm-launches-remdesivir-injection-in-the-indian-market/articleshow/77335802.cms
No comments:
Post a Comment